Molgramostim beneficial in autoimmune pulmonary alveolar proteinosis
In adults with autoimmune pulmonary alveolar proteinosis (aPAP), once-daily inhaled molgramostim, a recombinant human granulocyte-macrophage colony-stimulating factor, leads to a greater increase in pulmonary gas transfer than placebo, according to a study published in the Aug. 21/28 issue of the New England Journal of Medicine.